Show simple item record

dc.creatorAndia, Tatiana 
dc.creatorMantilla, Cesar 
dc.creatorMorales, Álvaro 
dc.creatorOrtiz, Santiago 
dc.creatorRodríguez Lesmes, Paul Andres 
dc.date.accessioned2020-10-20T23:25:37Z
dc.date.available2020-10-20T23:25:37Z
dc.date.created2020-10-20
dc.date.issued2020-10-20
dc.identifier.citationAndia, Tatiana; Mantilla, Cesar; Morales, Álvaro; Ortiz, Santiago; Rodríguez Lesmes, Paul Andrés (2020) Does price-cap regulation work for increasing access to contraceptives? Aggregate- and pharmacy-level evidence from Colombia. Universidad del Rosario, Department of Economics, Documentos de trabajo economía. 35 pp
dc.identifier.urihttps://repository.urosario.edu.co/handle/10336/30436
dc.descriptionAntecedentes: Los topes de precios mediante precios de referencia internacionales se utilizan ampliamente en todo el mundo, pero no tan comúnmente en los mercados over-the-counter (OTC). Estudiamos este tipo de regulación para el caso de los anticonceptivos orales en Colombia, que es un mercado OTC de facto. Objetivos: Se pretende establecer si la regulación desencadenó una respuesta competitiva dentro y a través de las categorías de productos (ingredientes activos farmacéuticos). También estudiamos si los productos regulados dirigidos a clientes de alto nivel socioeconómico se distribuyen ahora en farmacias de barrios de bajo nivel socioeconómico. Métodos: En primer lugar, utilizamos un modelo de panel lineal de efectos fijos para estimar el cambio en los precios y las cantidades asociadas a la nueva regulación para los productos regulados y no regulados utilizando datos administrativos a nivel de mayorista, según tres niveles de precios. Segundo, realizamos un estudio de auditoría con 213 farmacias comunitarias en la ciudad de Bogotá, Colombia. Visitamos las farmacias en dos ocasiones, antes y después de la introducción del tope de precios, recogiendo información sobre los precios y la disponibilidad de seis marcas seleccionadas. Hallazgos: El análisis a nivel mayorista revela una reducción de precios en productos regulados, y en los no regulados pero con un ingrediente activo regulado. Las cantidades comercializadas aumentan para los mismos tipos de productos, pero sólo para los de las categorías más caras. Además, las cantidades comercializadas de productos no regulados disminuyen. Aunque esta reducción de precios también se transmite a las farmacias, la disponibilidad de los anticonceptivos de gama alta y media incluidos en nuestro estudio de auditoría también disminuye. Proporcionamos pruebas sugestivas de que la reducción de la disponibilidad de los mismos fue mayor en las zonas de baja condición socioeconómica. Conclusiones: Las reglamentaciones sobre límites de precios que podrían parecer tan eficaces para reducir los precios y ampliar el acceso a nivel agregado podrían ocultar pautas de almacenamiento que afectan negativamente a la disponibilidad del producto para el consumidor final.
dc.description.abstractBackground: Price caps through international reference pricing are widely used around the World, but not so commonly in over-the-counter markets (OTC). We study this type of regulation for the case of oral contraceptives in Colombia, which is a de facto OTC market. Objectives: We aim to establish whether the regulation triggered a competitive response within and across product categories (active pharmaceutical ingredients). We also study whether regulated products targeted to customers from high socio-economic status are now distributed in pharmacies from low socio-economic neighborhoods. Methods: First, we use a fixed effects linear panel model to estimate the change in prices and quantities associated with the new regulation for regulated and non-regulated products using administrative data at the wholesale level, according to three price tiers. Second, we conducted an audit study with 213 community pharmacies in the city of Bogotá, Colombia. We visited pharmacies twice, before and after the introduction of the price cap, collecting information on prices and availability of six selected brands. Findings: The wholesale-level analysis reveals a price reduction in regulated and non-regulated products with a regulated active ingredient. Traded quantities increase for the same product types, but only for those in the most expensive categories. Besides, the traded quantities of non-regulated products decrease. Although this price reduction is also transmitted to community pharmacies, the availability of the high-end and mid-range contraceptives included in our audit study decreases as well. We provide suggestive evidence that reduction in the availability of was larger in areas of low socio-economic status. Conclusions: Price cap regulations that might look as effective in lowering prices and expanding access at the aggregate level could conceal stocking patterns that negatively affect the product availability for the final consumer.
dc.format.extent35
dc.format.mimetypeapplication/pdf
dc.language.isospa
dc.relation.urihttps://ideas.repec.org/p/col/000092/018484.html
dc.sourcereponame:Repositorio Institucional EdocUR
dc.sourceinstname:Universidad del Rosario
dc.subjectFarmacias
dc.subjectProductos farmacéuticos
dc.subjectClientes simulados
dc.subjectPíldoras anticonceptivas
dc.subject.ddcProblemas & servicios de bienestar social 
dc.titleDoes price-cap regulation work for increasing access to contraceptives? Aggregate- and pharmacy-level evidence from Colombia
dc.typeworkingPaper
dc.subject.keywordPharmacies
dc.subject.keywordPharmaceuticals
dc.subject.keywordSimulated clients
dc.subject.keywordContraceptive pills
dc.rights.accesRightsinfo:eu-repo/semantics/openAccess
dc.type.spaDocumento de trabajo
dc.rights.accesoAbierto (Texto Completo)
dc.source.bibliographicCitationAbbott III, T. A. (1995). Price regulation in the pharmaceutical industry: Prescription or placebo? Journal of Health Economics, 14(5):551–565
dc.source.bibliographicCitationAcosta, A., Ciapponi, A., Aaserud, M., Vietto, V., Austvoll-Dahlgren, A., Kosters, J. P., Vacca, ¨ C., Machado, M., Ayala, D. H. D., and Oxman, A. D. (2014). Pharmaceutical policies: effects of reference pricing, other pricing, and purchasing policies. Cochrane Database of Systematic Reviews, (10)
dc.source.bibliographicCitationAndia, T. (2018). El “efecto portafolio” de la regulacion de precios de medicamentos: La respuesta de la industria farmaceutica a la regulaci ´ on de precios de medicamentos en colombia”. ´ Washington, DC https://doi. org/10.18235/0001305
dc.source.bibliographicCitationAndia, T., Mantilla, C., Morales, A., Ortiz, S., and Rodr´ıguez, P. (2020). Extracting low-cost signals of quality control in community pharmacies: a simulated client study in Bogota. Documentos ´ de trabajo, Universidad del Rosario
dc.source.bibliographicCitationBalafoutas, L., Kerschbamer, R., and Sutter, M. (2015). Second-degree moral hazard in a real-world credence goods market. The Economic Journal, 127(599):1–18
dc.source.bibliographicCitationBauhoff, S. (2012). Do health plans risk-select? an audit study on germany’s social health insurance. Journal of Public Economics, 96(9-10):750–759
dc.source.bibliographicCitationBitzer, J. (2015). Progestogens in contraception. In Carp, H., editor, Progestogens in Obstetrics and Gynecology, chapter 8, pages 111–128. Springer
dc.source.bibliographicCitationBrekke, K. R., Canta, C., and Straume, O. R. (2016). Reference pricing with endogenous generic entry. Journal of health economics, 50:312–329
dc.source.bibliographicCitationCosta-Font, J., McGuire, A., and Varol, N. (2014). Price regulation and relative delays in generic drug adoption. Journal of health economics, 38:1-9
dc.source.bibliographicCitationCurrie, J., Lin, W., and Zhang, W. (2011). Patient knowledge and antibiotic abuse: Evidence from an audit study in china. Journal of Health Economics, 30(5):933–949
dc.source.bibliographicCitationDas, J., Holla, A., Mohpal, A., and Muralidharan, K. (2016). Quality and accountability in health care delivery: audit-study evidence from primary care in india. American Economic Review, 106(12):3765–99
dc.source.bibliographicCitationDas, J., Woskie, L., Rajbhandari, R., Abbasi, K., and Jha, A. (2018). Rethinking assumptions about delivery of healthcare: implications for universal health coverage. bmj, 361:k1716
dc.source.bibliographicCitationFrank, R. G. and Salkever, D. S. (1992). Pricing, patent loss and the market for pharmaceuticals. Southern Economic Journal, pages 165–179
dc.source.bibliographicCitationGuerrero, R., Prada, S., Perez, A., Duarte, J., and Aguirre, A. (2015). Universal Health Coverage ´ Assessment: Colombia. Technical report, Global Network for Health Equity
dc.source.bibliographicCitationKwan, A., Daniels, B., Bergkvist, S., Das, V., Pai, M., and Das, J. (2019). Use of standardised patients for healthcare quality research in low-and middle-income countries. BMJ Global Health, 4(5):e001669
dc.source.bibliographicCitationList, J. A. (2004). The nature and extent of discrimination in the marketplace: Evidence from the field. Quarterly Journal of Economics, 119(1):49–89
dc.source.bibliographicCitationMadden, J. M., Quick, J. D., Ross-Degnan, D., and Kafle, K. K. (1997). Undercover careseekers: simulated clients in the study of health provider behavior in developing countries. Social Science & Medicine, 45(10):1465–1482
dc.source.bibliographicCitationMiller, R. and Goodman, C. (2016). Performance of retail pharmacies in low-and middle-income asian settings: a systematic review. Health policy and planning, 31(7):940–953
dc.source.bibliographicCitationMinisterio de Salud y Proteccion Social (2019). Boletinın 03 - SISMED. Technical report, Ministerio de Salud y Proteccion Social, Bogota, D.C
dc.source.bibliographicCitationMoreno, G., van Eijndhoven, E., Benner, J., and Sullivan, J. (2017). The long-term impact of price controls in medicare part d. In Forum for health economics & policy, volume 20. De Gruyter
dc.source.bibliographicCitationPan American Health Organization, United Nations Population Fund, and United Nations Children’s Fund (2016). Accelerating progress toward the reduction of adolescent pregnancy in Latin America and the Caribbean. Technical report, Pan American Health Organization, Washington, D.C., USA
dc.source.bibliographicCitationPrada, S. I., Soto, V. E., Andia, T. S., Vaca, C. P., Morales, A. A., M ´ arquez, S. R., and Gaviria, A. ´ (2018). Higher pharmaceutical public expenditure after direct price control: improved access or induced demand? the colombian case. Cost Effectiveness and Resource Allocation, 16(1):8
dc.source.bibliographicCitationSitruk-Ware, R., Nath, A., and Mishell, D. (2012). Contraception technology: Past, present and future. Contraception, 87
dc.source.bibliographicCitationSmith, F. (2009). The quality of private pharmacy services in low and middle-income countries: a systematic review. Pharmacy world & science, 31(3):351–361
dc.source.bibliographicCitationSood, N., De Vries, H., Gutierrez, I., Lakdawalla, D. N., and Goldman, D. P. (2008). The effect of regulation on pharmaceutical revenues: Experience in nineteen countries: If the united states implemented price controls and negotiations similar to those in other developed countries, us revenues would fall by as much as 20.3 percent. Health Affairs, 27(Suppl1):w125–w137
dc.source.bibliographicCitationUNESCO (2017). Early and unintended pregnancy & the education sector: Evidence review and recommendations. Technical report, UNESCO, Paris
dc.source.bibliographicCitationUnited Nations (2020). World Fertility 2019: Early and later childbearing among adolescent women. Technical report, United Nations, New York, NY
dc.source.bibliographicCitationVacca, C., Nino, C., and Reveiz, L. (2011). Restriction of antibiotic sales in pharmacies in bogota,´ colombia: a descriptive study. Revista Panamericana de Salud Publica, 30(6):586–591
dc.source.bibliographicCitationVon der Schulenburg, F., Vandoros, S., and Kanavos, P. (2011). The effects of drug market regulation on pharmaceutical prices in europe: overview and evidence from the market of ace inhibitors. Health economics review, 1(1):18
dc.source.bibliographicCitationWafula, F. N., Miriti, E. M., and Goodman, C. A. (2012). Examining characteristics, knowledge and regulatory practices of specialized drug shops in sub-saharan africa: a systematic review of the literature. BMC health services research, 12(1):223
dc.source.bibliographicCitationWatson, M. C., Norris, P., and Granas, A. (2006). A systematic review of the use of simulated patients and pharmacy practice research. International Journal of Pharmacy Practice, 14(2):83– 93
dc.source.bibliographicCitationWiggins, S. N. and Maness, R. (2004). Price competition in pharmaceuticals: the case of antiinfectives. Economic Inquiry, 42(2):247–263
dc.source.bibliographicCitationWorld Health Organization (2011). Preventing Early Pregnancy and Poor Reproductive Outcomes Among Adolescents in Developing Countries. Technical report, World Health Organization, Geneva
dc.source.bibliographicCitationWorld Health Organization (2015). WHO Guideline on Country Pharmaceutical Pricing Policies. Technical report, World Health Organization, Geneva
dc.source.bibliographicCitationZhang, W., Guh, D., Sun, H., Marra, C. A., Lynd, L. D., and Anis, A. H. (2016). The impact of price-cap regulations on exit by generic pharmaceutical firms. Medical care, 54(9):884–890
dc.subject.jelI110
dc.subject.jelI150
dc.subject.jelI180
dc.contributor.gruplacGrupo de Investigaciones. Facultad de Economía. Universidad del Rosario
dc.relation.citationTitleSerie Documentos de trabajo. Economía


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record